MHC II immunogenicity shapes the neoepitope landscape in human tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jeong Yeon | - |
dc.contributor.author | Cha, Hongui | - |
dc.contributor.author | Kim, Kyeonghui | - |
dc.contributor.author | Sung, Changhwan | - |
dc.contributor.author | An, Jinhyeon | - |
dc.contributor.author | Bang, Hyoeun | - |
dc.contributor.author | Kim, Hyungjoo | - |
dc.contributor.author | Yang, Jin Ok | - |
dc.contributor.author | Chang, Suhwan | - |
dc.contributor.author | Shin, Incheol | - |
dc.contributor.author | Noh, Seung-Jae | - |
dc.contributor.author | Shin, Inkyung | - |
dc.contributor.author | Cho, Dae-Yeon | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Choi, Jung Kyoon | - |
dc.date.accessioned | 2023-05-03T10:15:15Z | - |
dc.date.available | 2023-05-03T10:15:15Z | - |
dc.date.created | 2023-02-08 | - |
dc.date.issued | 2023-02 | - |
dc.identifier.issn | 1061-4036 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/185081 | - |
dc.description.abstract | Despite advances in predicting physical peptide-major histocompatibility complex I (pMHC I) binding, it remains challenging to identify functionally immunogenic neoepitopes, especially for MHC II. By using the results of > 36,000 immunogenicity assay, we developed a method to identify pMHC whose structural alignment facilitates T cell reaction. Our method predicted neoepitopes for MHC II and MHC I that were responsive to checkpoint blockade when applied to > 1,200 samples of various tumor types. To investigate selection by spontaneous immunity at the single epitope level, we analyzed the frequency spectrum of > 25 million mutations in > 9,000 treatment-naive tumors with > 100 immune phenotypes. MHC II immunogenicity specifically lowered variant frequencies in tumors under high immune pressure, particularly with high TCR clonality and MHC II expression. A similar trend was shown for MHC I neoepitopes, but only in particular tissue types. In summary, we report immune selection imposed by MHC II-restricted natural or therapeutic T cell reactivity. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PORTFOLIO | - |
dc.title | MHC II immunogenicity shapes the neoepitope landscape in human tumors | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shin, Incheol | - |
dc.identifier.doi | 10.1038/s41588-022-01273-y | - |
dc.identifier.scopusid | 2-s2.0-85145922812 | - |
dc.identifier.wosid | 000909814400001 | - |
dc.identifier.bibliographicCitation | NATURE GENETICS, v.55, no.2, pp.221 - 231 | - |
dc.relation.isPartOf | NATURE GENETICS | - |
dc.citation.title | NATURE GENETICS | - |
dc.citation.volume | 55 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 221 | - |
dc.citation.endPage | 231 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Early Access | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.subject.keywordPlus | IMMUNE CHECKPOINT BLOCKADE | - |
dc.subject.keywordPlus | CTLA-4 BLOCKADE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | NEOANTIGENS | - |
dc.subject.keywordPlus | SENSITIVITY | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | SELECTION | - |
dc.subject.keywordPlus | FEATURES | - |
dc.identifier.url | https://www.nature.com/articles/s41588-022-01273-y | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.